Department of Surgery, Ewha Womans University College of Medicine, 260, Gonghang-Daero, Gangseo-Gu, Seoul, 07804, South Korea.
Tech Coloproctol. 2023 Dec;27(12):1183-1189. doi: 10.1007/s10151-023-02857-4. Epub 2023 Oct 3.
The short-term outcomes of robotic right hemicolectomy for right colon cancer have been extensively studied in comparison to conventional laparoscopic right hemicolectomy. However, the long-term oncological outcomes of the two approaches have not been investigated, except in single-center retrospective studies. Therefore, this meta-analysis aimed to investigate the long-term oncological outcomes of robotic right hemicolectomy compared with those of laparoscopic right hemicolectomy for right colon cancer.
We searched PubMed, EMBASE, and Cochrane Library for studies comparing robotic right hemicolectomy with conventional laparoscopic right hemicolectomy for right colon cancer from the date of database inception to August 2022. For survival data extraction, hazard ratios (HRs) with 95% confidence intervals (CI) were calculated using random- or fixed-effects models from the Kaplan-Meier survival curves in the included studies. All calculations and statistical tests were performed using Review Manager software, version 5.4.
A total of 523 patients (robotic right hemicolectomy, 230; laparoscopic right hemicolectomy, 293) from five studies were included in this meta-analysis. There were no significant differences in patient characteristics between the two groups. In terms of pathological characteristics, TNM stage was not different and revealed no differences in the number of harvested lymph nodes even though a larger number of lymph nodes were harvested in the robotic group in one study. Pooled analyses demonstrated no significant difference in disease-free survival (HR 0.72, 95% CI 0.46-1.13, p = 0.15) and overall survival (HR 0.73, 95% CI 0.48-1.13, p = 0.16) between robotic and laparoscopic right hemicolectomy for right colon cancer.
Robotic right hemicolectomy for right colon cancer is comparable with conventional laparoscopic right hemicolectomy in terms of long-term oncological survival. More prospective, multicenter, randomized trials are necessary to determine the oncologic safety of robotic right hemicolectomy.
与传统腹腔镜右半结肠切除术相比,机器人右半结肠切除术的短期疗效已得到广泛研究。然而,除了单中心回顾性研究外,两种方法的长期肿瘤学结果尚未得到研究。因此,本荟萃分析旨在研究机器人右半结肠切除术与腹腔镜右半结肠切除术治疗右半结肠癌的长期肿瘤学结果。
我们检索了 PubMed、EMBASE 和 Cochrane Library 数据库,以获取自数据库成立以来至 2022 年 8 月期间比较机器人右半结肠切除术与传统腹腔镜右半结肠切除术治疗右半结肠癌的研究。对于生存数据提取,使用纳入研究中 Kaplan-Meier 生存曲线中的随机或固定效应模型计算风险比(HR)及其 95%置信区间(CI)。所有计算和统计检验均使用 Review Manager 软件,版本 5.4 进行。
共有来自五篇研究的 523 名患者(机器人右半结肠切除术 230 例,腹腔镜右半结肠切除术 293 例)纳入本荟萃分析。两组患者的临床特征无显著差异。在病理特征方面,TNM 分期无差异,尽管在一项研究中,机器人组的淋巴结检出数量更多,但淋巴结检出数量无差异。荟萃分析显示,机器人右半结肠切除术与腹腔镜右半结肠切除术治疗右半结肠癌在无病生存率(HR 0.72,95%CI 0.46-1.13,p=0.15)和总生存率(HR 0.73,95%CI 0.48-1.13,p=0.16)方面无显著差异。
机器人右半结肠切除术治疗右半结肠癌在长期肿瘤生存方面与传统腹腔镜右半结肠切除术相当。需要更多前瞻性、多中心、随机试验来确定机器人右半结肠切除术的肿瘤学安全性。